Sensus squeaks out with $11M IPO for low-energy x-ray treatment

Sensus Healthcare ($SRTSU) raised $11 million by selling two million units at $5.50. That was after the company had reduced its proposed price of $6.25. This is the third med tech IPO in the U.S. this week; Clearside Biomedical ($CLSD) similarly had to reduce its price ahead of the IPO but traded up in its first day. Sensus was also gaining ground in early trading--up 7% in early trading to $5.90. The company offers superficial radiation treatment devices for non-melanoma skin cancer and keloids with installations in more than 220 locations. More

Suggested Articles

Grail published new data showing that its cancer-screening blood test is now able to spot more than 50 types of the disease and across all stages.

Battelle received an emergency go-ahead from the FDA over the weekend to deploy its decontamination system for N95 respirator masks.

The limited supply of ventilators is one of the chief concerns facing hospitals as they prepare for more COVID-19 cases.